A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
Genentech, Inc.
National Cancer Institute (NCI)
OncoC4, Inc.
Pfizer
USWM, LLC (dba US WorldMeds)
ViroMissile, Inc.
Novartis
University Health Network, Toronto
NeoTX Therapeutics Ltd.
Actym Therapeutics, Inc.
Pfizer
Arcus Biosciences, Inc.
University of Virginia
Eli Lilly and Company
Columbia University
Revolution Medicines, Inc.
Vincerx Pharma, Inc.
NGM Biopharmaceuticals, Inc
ADC Therapeutics S.A.
Pliant Therapeutics, Inc.
NGM Biopharmaceuticals, Inc
Celldex Therapeutics
Adaptimmune
University of Florida
Fate Therapeutics
Prelude Therapeutics
Quadriga Biosciences, Inc.
Ludwig Institute for Cancer Research
Revolution Medicines, Inc.
Incyte Corporation
Mie University
Incyte Corporation
Abramson Cancer Center at Penn Medicine
Mie University
Santa Maria Biotherapeutics
Roswell Park Cancer Institute
Shenzhen Second People's Hospital
City of Hope Medical Center
ImmunoFrontier, Inc.
Dartmouth-Hitchcock Medical Center
Altor BioScience
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Mannkind Corporation
Case Comprehensive Cancer Center
Fujian Longhua Pharmaceutical Co. Ltd
NS Pharma, Inc.